PDCD1 and neoplasm: demonstrated that ex vivo engineered HER2-CAR-M could remodel the tumour microenvironment and sensitise tumours to PD-1 checkpoint blockade (36), indicating a synergistic role for CAR-Ms in combination immunotherapies.